Genmab — Juni 2024
-
For dem, der gerne vil se, hvordan overliggeren befinder sig i nsclc first line - https://ascopubs.org/doi/10.1200/JCO.21.01497
-
…men derfor kan Acasunlimab jo stadig komme i first line. Sjovt som ORR stiger - men OS i first line er ikke markant anderledes end OS i second line…
-
Det bliver super interessant at følge OS data efter din trøffel-gris action ifht protokollen
-
Lahn , i think the original link does not work anymore, it is in this list, p609 i believe, maybe you can search from there https://sitc.sitcancer.org/2019/abstracts/titles/index.php?filter=4-1bb
-
Thx, found it on pubmed by title https://pubmed.ncbi.nlm .nih.gov/37259060/
-
An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity - PubMed
We generated an Fc-muted anti-PD-L1x4-1BB BsAb, HK010, with a distinguished structural interaction with PD-L1 and 4-1BB that exhibits a synergistic antitumor effect by blocking the PD-1/PD-L1 signaling pathway and stimulating the 4-1BB signaling pathway simultaneously. It is strictly dependent on th …
PubMed (pubmed.ncbi.nlm.nih.gov)
-
Perhaps news from FDA on Epco RR FL later tonight?
-
Think PDUFA date is next Friday 28th of June. https://www.guidelinecentral.com/blog/june-2024-fda-pdufa-dates/
-
Linket fra Winkels interview der ligger højere oppe i tråden er ganske interessant på flere punkter. 13:30 inde snakker han om samarbejdet med Biontech og at de har fundet en måde at påvirke immunsystemet på byond Ctla-4 (Ipilimumab) som giver en meget hurtig effekt på tumore. Vi har nu set Gen1046 resultater og at det ikke er det stof han henviser til i de kommentarer. Der kan potentielt være Gen1042 !
-
-
Han omtaler også, at ADC teknologien fra Profound giver dem teknologien til at forbedre resultaterne effekten yderligere. Samt at den teknologi er meget lettere at arbejde med en antistofferne alene. Profounds teknologi omtaler han som unik og det skal han selvfølgelige
De 5 år som de var om udvikling af epco kan vi tillægge til nu, hvor de har Profounds ADC maskine og derfor forstå, hvorfor Winkel tidligere har udtalt “Will add significant value to Gennmab in early 30 th” -
Forme ProfoundBio CEO Baiteng Zhao is now the General Manager, China for
Genmab https://www.linkedin.com/in/baiteng-zhao-b40b804 -
Der mangler vist et modspil til KYSO - hvad med without a shred of evidence - wasoe - eller på dansk “vassåe?”
-
Godmorgen
-
NOVO/GENMAB: FRONTIER2 data presented at ISTH 2024 showed that up to 95% of people, who had no prior prophylaxis treatment, experienced zero treated bleeds while on Mim8 https://proinvestor.com/boards/121038
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind